The DOI matches its Crossref record; 117 of the 120 references it cites were found in a registry or an index.
The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS
Open accessAbstract
X-linked juvenile retinoschisis (XLRS) is an early-onset progressive inherited retinopathy affecting males. It is characterized by abnormalities in the macula, with formation of cystoid retinal cavities, frequently accompanied by splitting of the retinal layers, impaired synaptic transmission of visual signals, and associated loss of visual acuity. XLRS is caused by loss-of-function mutations in the retinoschisin gene located on the X chromosome (RS1, MIM 30083). While proof-of-concept studies for gene augmentation therapy have been promising in in vitro and rodent models, clinical trials in XLRS patients have not been successful thus far. We performed a systematic literature investigation using search strings related to XLRS and gene therapy in in vivo and in vitro models. Three rounds of screening (title/abstract, full text and qualitative) were performed by two independent reviewers until consensus was reached. Characteristics related to study design and intervention were extracted from all studies. Results were divided into studies using (1) viral and (2) non-viral therapies. All in vivo rodent studies that used viral vectors were assessed for quality and risk of bias using the SYRCLE’s risk-of-bias tool. Studies using alternative and non-viral delivery techniques, either in vivo or in vitro, were extracted and reviewed qualitatively, given the diverse and dispersed nature of the information. For in-depth analysis of in vivo studies using viral vectors, outcome data for optical coherence tomography (OCT), immunohistopathology and electroretinography (ERG) were extracted. Meta-analyses were performed on the effect of recombinant adeno-associated viral vector (AAV)-mediated gene augmentation therapies on a- and b-wave amplitude as well as the ratio between b- and a-wave amplitudes (b/a-ratio) extracted from ERG data. Subgroup analyses and meta-regression were performed for model, dose, age at injection, follow-up time point and delivery method. Between-study heterogeneity was assessed with a Chi-square test of homogeneity (I2). We identified 25 studies that target RS1 and met our search string. A total of 19 of these studies reported rodent viral methods in vivo. Six of the 25 studies used non-viral or alternative delivery methods, either in vitro or in vivo. Of these, five studies described non-viral methods and one study described an alternative delivery method. The 19 aforementioned in vivo studies were assessed for risk of bias and quality assessments and showed inconsistency in reporting. This resulted in an unclear risk of bias in most included studies. All 19 studies used AAVs to deliver intact human or murine RS1 in rodent models for XLRS. Meta-analyses of a-wave amplitude, b-wave amplitude, and b/a-ratio showed that, overall, AAV-mediated gene augmentation therapy significantly ameliorated the disease phenotype on these parameters. Subgroup analyses and meta-regression showed significant correlations between b-wave amplitude effect size and dose, although between-study heterogeneity was high. This systematic review reiterates the high potential for gene therapy in XLRS, while highlighting the importance of careful preclinical study design and reporting. The establishment of a systematic approach in these studies is essential to effectively translate this knowledge into novel and improved treatment alternatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic structure representing the retinoschisin (RS1) gene (A), protein diagram (B), the quaternary structure of the protein (C), and hallmarks of X-linked juvenile retinoschisis (XLRS) (D). (A) (Adapted from Hahn et al. [4]). An overview of RS1 shows the localization and variants within the gene. Colored boxes represent the six exons, and the numbers within the boxes represent their size in nucleotides. The type of variant is presented in the legend, and the frequency and distribution are described within the gene structure. Splice site (n = 38), missense (n = 101), and deletion variants (n = 11) are the three most common variants. (B) Overview of the RS1 protein, featuring the signal peptide domain, the RS1 domain, the discoidin domain and the C-terminal domain. (C) The top and side view of the octamer and double octamer. (D) Fundus photograph of a 35-year old patient with a hemizygous c.428A > T p.(Asp143Val) mutation in the RS1 gene patient with XLRS, and optical coherence tomography image showing macular schisis (asterisk) in this patient with XLRS.](https://figures.cochat.ai/paper-figures/2b6d4ed5e9c04e7180b66e92e65ebac9/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-1.jpg)

![Figure 3 All in vivo studies were assessed on their risk of bias using the SYRCLE tool [69]. (A) The studies were assessed on whether any information was provided about ethical approval, conflicts of interest, calculation of sample sizes, blinding, or randomization. (B) The studies were assessed on possible risk of selection, performance, detection, outcome reporting, attrition and other biases. When the contralateral eye was used as the (internal) control, questions for random housing and allocation concealment were answered with not-applicable (N/A). Most studies received an unclear risk-of-bias score, due to a lack of reporting of essential quality indicators.](https://figures.cochat.ai/paper-figures/50ae7ab620ce4c60b2413a1e899c349a/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-3.jpg)


![Figure 6 The overall effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on a-wave amplitudes with integrated dosage subgroup analysis. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this meta-analysis were Bush2016 [85], Scruggs2022 [88], Min2005 [77], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. The left side of the null effect line favors the control, whereas the right side of the null effect line favors treatment. The overall effect size (0.75 [0.56, 0.94]) was computed with a random effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were not found to be highly heterogeneous (I2 = 17.1%). SMD = standardized mean difference, CI = confidence interval.](https://figures.cochat.ai/paper-figures/8bea9c26adce47648e282ee554eabb8b/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-6.jpg)
![Figure 7 The overall weighted effect size of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude. The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Min2005 [77], Molday2006 [78], Janssen2008 [80], Byrne2014 [54], Bush2016 [85], Marangoni2017 [87], and Scruggs2022 [88]. The standardized mean differences (SMDs) with 95% confidence intervals (CI) of each experimental group are displayed in a forest plot. The dashed black line represents no treatment effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. Included studies were assessed for homogeneity with a Chi-square test and were found to be highly heterogeneous (I2 = 76.5%).](https://figures.cochat.ai/paper-figures/79813cddee0b4a289c864a7cc2f733e0/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-7.jpg)
![Figure 8 The effect sizes of adeno-associated viral vector (AAV)-mediated gene augmentation therapy on the b-wave amplitude for subgroups mouse model, delivery method, dose, age at injection, and follow-up time point. The black dashed line indicates the null effect. Values left of the null effect line favor the control, whereas values right of the null effect line favor the treatment. The overall effect size (1.44 [1.11, 1.77]) was computed with a random-effects model and is represented by a green diamond and dashed line. The between-study heterogeneity was high (I2 = 76.5%), and therefore these subgroup analyses serve for orientational purposes only. Rs1h = retinoschisin, KO = knock-out, IVI = intravitreal injection, SRI = subretinal injection, M = months of age, MPI = months post-injection, SMD = standardized mean difference, CI = confidence interval.](https://figures.cochat.ai/paper-figures/9722fc9a5485427297d9d0f3fd2d9f66/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-8.jpg)
![Figure 9 The overall weighted effect size of AAV-mediated gene augmentation therapy on the ratio between the b- and a-wave amplitudes (b/a-ratio). The studies included in this meta-analysis were assigned study IDs according to First Author Publication year, and experimental groups within one publication are distinguished by labeling them a through z. The studies included in this analysis were Bush2016 [85], Park2009 [82], and Marangoni2017 [87]. The results are staggered per subgroup (total dose smaller than 4 × 109 viral genomes/eye (vg/eye) and larger than 4 × 109 vg/eye). The black circles represent the overall subgroup effect size, and the green diamond represents the overall weighted effect size. The black dashed line indicates the null effect. Values left of the null effect line favor control, whereas values right of the null effect line favors treatment. The overall effect size (1.08 [0.42, 1.74]) was computed with a random-effects model and is represented by a green diamond and dashed line. The black circles indicate the overall subgroup effect size. A Chi-square test of homogeneity revealed high levels of between-study heterogeneity (I2 = 90.7%). SMD = standardized mean difference, CI = confidence interval.](https://figures.cochat.ai/paper-figures/234e63e12b584ff69837ea02d2eadcde/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-9.jpg)

![Figure 11 The classification of alternative delivery and non-viral delivery methods. The first classification is alternative delivery and non-viral delivery methods. In the former, the exosome-associated adeno-assiocated viral vectors (AAVs) are classified [93]. Within the non-viral methods category, a second classification can be made: chemical and physical methods. The physical methods contain the electroporation method [58], while the chemical methods can be divided into organic (solid lipid nanoparticles [63,95]) or inorganic (dual supramolecules nanoparticles [96] and carboxylated nanodiamonds [97]) vectors. In each category, a schematic representation of the vectors used for RS1 or gene editing constructs delivery is included to illustrate the building blocks used in each vector. Dual supramolecular nanoparticle and carboxylated nanodiamond representations have been adapted from Chou et al. and Yang et al., respectively [96,97]. Outlined with a yellow line are the studies designed for gene augmentation, whereas those designed for gene editing are marked with a green line. XLRS = X-linked juvenile retinoschisis, RS1 = retinoschisin, ad = adamantane-grafted, PEG = polyethylene glycol, TAT = adenosine-5’-rp-alpha-thio-triphosphate, CD-PEI = carbon dot-polyethylenimine, GFP = green fluorescent protein, sgRNA = single guide RNA.](https://figures.cochat.ai/paper-figures/45588f2d31a54ac49e396145d126cc3d/the-road-towards-gene-therapy-for-x-linked-juvenile-retinoschisis-a-systematic-figure-11.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, Xlinked retinoschisis demonstrates increased retinal fragility, making the detachment of posterior hyaloid and subretinal injection highly chal lenging (van der Veen et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as van der Veen et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415 · cited 2×
“Secondly, risk-of-bias assessment was conducted based on ten entries, which aimed to evaluate selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases [69].”
MethodAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Despite these limitations, AAVs were approved by the Food and Drug administration (FDA) and European Medicine Agency (EMA) to treat RPE65 -associated Leber’s congenital amaurosis, and are currently used in ongoing clinical trial for a broad range of inherited retinal diseases [48–51].”
BackgroundBase editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
An atlas of the protein-coding genes in the human, pig, and mouse brain
Sjöstedt, E., Zhong, W., Fagerberg, L., Karlsson, M., Mitsios, N., Adori, C., Oksvold, P., Edfors, F., Limiszewska, A., Hikmet, F., et al. (2020) · Science · doi:10.1126/science.aay5947 · Cited by 1,151
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“While non-viral vectors have been demonstrated to have lower immunogenicity and toxicity, they generally also show lower transduction efficiency; as a consequence, further optimization is still required [65,114].”
BackgroundLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“Nevertheless, and despite the eye’s relative immune privilege, immune responses to high AAV doses are still reported in in vivo studies [55,56].”
Background
Research works printed but not linked: 1
- Haas, 1898, Ueber das Zusammenvorkommen von Veraenderungen der Retina und Choroidea, Arch. Augenheilkd., 37, 343
Cited by
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“For example, X-linked retinoschisis demonstrates increased retinal fragility, making the detachment of posterior hyaloid and subretinal injection highly challenging (van der Veen et al., 2024).”
A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases
Alsalloum, A., Gornostal, E. A., Mingaleva, N., Pavlov, R. E., Kuznetsova, E., Antonova, E., Nadzhafova, A., Колотова, Д. Е., Кадышев, В. В., Mityaeva, O. N., et al. (2024) · Cells · doi:10.3390/cells13201706 · Cited by 20
Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Ахметшин, Р. Ф., Bulgar, S. N., & Rizvanov, A. A. (2025) · Biomedicines · doi:10.3390/biomedicines13020365 · Cited by 19
Hensman, J., Allali, Y. E., Almushattat, H., de Vente, C., Sánchez, C. I., & Boon, C. J. F. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17495 · Cited by 7
Self-citationA retrospective longitudinal study of 52 Finnish patients with X‐linked retinoschisis
Järvinen, M. A., Baraas, R. C., Majander, A. S., Backlund, M., Krootila, J., Paavo, M., Lindahl, P., Vasara, K., Sankila, E., Kivelä, T., et al. (2024) · Acta Ophthalmologica · doi:10.1111/aos.16776 · Cited by 7
Metadata
- Authors
- van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F.
- Affiliations
- Department of Ophthalmology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Amsterdam UMC Location University of Amsterdam (NL)
- Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Leiden University (NL)
- Corresponding author
- Boon, Camiel J. F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-01-19
- Volume
- 25
- Issue
- 2
- Pages
- 1267
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10816913
- OpenAlex
- W4391107036
- Cited by
- 14
- References
- 120
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 2
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- Funders
- NWO-ALW (Nederlandse Organisatie voor Wetenschappelijk Onderzoek-Aard en Levenswetenschappen) (09150171910048)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- X-linked retinoschisis, retinoschisin, RS1, gene therapy, gene augmentation therapy, adeno-associated virus vectors, viral vectors, non-viral gene delivery, rodent models, cell-based models, electroretinogram, retinal function, risk of bias assessment
- MeSH terms
- Animals, Electroretinography, Eye Proteins, Humans, Male, Mutation, Retina, Genetic Therapy, Retinoschisis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS. https://app.cochat.ai/papers/10.3390/ijms25021267
- The paper
- van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024). The Road towards Gene Therapy for X-Linked Juvenile Retinoschisis: A Systematic Review of Preclinical Gene Therapy in Cell-Based and Rodent Models of XLRS. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.